title: Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
abstract: The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.
authors.affiliation: Department of Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria. oagbaji@yahoo.com
authors.forename: Oche
authors.initials: O
authors.lastname: Agbaji
authors.forename: Chloe L
authors.initials: CL
authors.lastname: Thio
authors.forename: Seema
authors.initials: S
authors.lastname: Meloni
authors.forename: Camilla
authors.initials: C
authors.lastname: Graham
authors.forename: Mohammed
authors.initials: M
authors.lastname: Muazu
authors.forename: Ladep
authors.initials: L
authors.lastname: Nimzing
authors.forename: John
authors.initials: J
authors.lastname: Idoko
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Sankalé
authors.forename: Ernest
authors.initials: E
authors.lastname: Ekong
authors.forename: Robert
authors.initials: R
authors.lastname: Murphy
authors.forename: Phyllis
authors.initials: P
authors.lastname: Kanki
authors.forename: Claudia
authors.initials: C
authors.lastname: Hawkins
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000480:Alkynes; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048588:Benzoxazines / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood*; D060085:Coinfection / Q000097:blood / Q000821:virology*; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000009:adverse effects; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use; D009549:Nigeria; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D018119:Stavudine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000480:Alkynes; D044966:Anti-Retroviral Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D009943:Organophosphorus Compounds; D012367:RNA, Viral; D003841:Deoxycytidine; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine; D018119:Stavudine; D000410:Alanine Transaminase; C098320:efavirenz